| Year |
Citation |
Score |
| 2024 |
Muzi M, Peterson LM, Specht JM, Hippe DS, Novakova-Jiresova A, Lee JH, Kurland BF, Mankoff DA, Obuchowski N, Linden HM, Kinahan PE. Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials. Research Square. PMID 38313279 DOI: 10.21203/rs.3.rs-3818932/v1 |
0.385 |
|
| 2023 |
Mankoff D, Balogová S, Dunnwald L, Dehdashti F, DeVries E, Evangelista L, Van Kruchten M, Vaz SC, Fowler A, Linden H, Ulaner GA. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[F]Fluoro-17β-Estradiol PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 38071554 DOI: 10.2967/jnumed.123.266938 |
0.422 |
|
| 2023 |
Kazerouni AS, Peterson LM, Jenkins I, Novakova-Jiresova A, Linden HM, Gralow JR, Hockenbery DM, Mankoff DA, Porter PL, Partridge SC, Specht JM. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer. Breast Cancer Research : Bcr. 25: 138. PMID 37946201 DOI: 10.1186/s13058-023-01722-4 |
0.414 |
|
| 2023 |
Linden HM, Mankoff DA. Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36988617 DOI: 10.1158/1078-0432.CCR-23-0393 |
0.302 |
|
| 2023 |
Ulaner GA, Mankoff DA, Clark AS, Fowler AM, Linden HM, Peterson LM, Dehdashti F, Kurland BF, Mortimer J, Mouabbi J, Moon DH, de Vries EGE. Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-F-Fluoro-17β-Fluoroestradiol. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 64: 351-354. PMID 36863779 DOI: 10.2967/jnumed.123.265420 |
0.364 |
|
| 2023 |
O'Brien SR, Edmonds CE, Lanzo SM, Weeks JK, Mankoff DA, Pantel AR. F-Fluoroestradiol: Current Applications and Future Directions. Radiographics : a Review Publication of the Radiological Society of North America, Inc. 43: e220143. PMID 36821506 DOI: 10.1148/rg.220143 |
0.322 |
|
| 2022 |
Pantel AR, Gitto SB, Makvandi M, Kim H, Medvedv S, Weeks JK, Torigian DA, Hsieh CJ, Ferman B, Latif NA, Tanyi JL, Martin LP, Lanzo SM, Liu F, Cao Q, ... ... Mankoff DA, et al. [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36441795 DOI: 10.1158/1078-0432.CCR-22-1602 |
0.334 |
|
| 2022 |
Makhlin I, Korhonen KE, Martin ML, Gillman J, Schubert E, Pantel AR, Mankoff DA, Clark AS. F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer. Radiology. Imaging Cancer. 4: e220032. PMID 36269154 DOI: 10.1148/rycan.220032 |
0.42 |
|
| 2022 |
Mankoff DA, Clark AS, Edmonds CE, O'Brien SR, Pantel AR. 16α-[F]Fluoro-17β-Estradiol Positron Emission Tomography to Measure Regional Estrogen Receptor Expression in Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201055. PMID 36041088 DOI: 10.1200/JCO.22.01055 |
0.31 |
|
| 2022 |
Zhou R, Choi H, Cao J, Pantel A, Gupta M, Lee H, Mankoff D. F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 35772960 DOI: 10.2967/jnumed.122.264152 |
0.422 |
|
| 2022 |
Edmonds CE, O'Brien SR, Mankoff DA, Pantel AR. Novel applications of molecular imaging to guide breast cancer therapy. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 22: 31. PMID 35729608 DOI: 10.1186/s40644-022-00468-0 |
0.445 |
|
| 2022 |
Pantel AR, Viswanath V, Muzi M, Doot RK, Mankoff DA. Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 63: 342-352. PMID 35232879 DOI: 10.2967/jnumed.121.263518 |
0.384 |
|
| 2022 |
Lee HS, Schwarz SW, Schubert EK, Chen DL, Doot RK, Makvandi M, Lin LL, McDonald ES, Mankoff DA, Mach RH. The Development of F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1. Radiology. Imaging Cancer. 4: e210070. PMID 35089089 DOI: 10.1148/rycan.210070 |
0.385 |
|
| 2022 |
Mankoff DA, Sellmyer MA. PET of Fibroblast-Activation Protein for Breast Cancer Diagnosis and Staging. Radiology. 302: 48-49. PMID 34636639 DOI: 10.1148/radiol.2021212098 |
0.341 |
|
| 2021 |
Sellmyer MA, Lee IK, Mankoff DA. Building the Bridge: Molecular Imaging Biomarkers for 21 Century Cancer Therapies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 34446450 DOI: 10.2967/jnumed.121.262484 |
0.319 |
|
| 2021 |
Romine PE, Peterson LM, Kurland BF, Byrd DW, Novakova-Jiresova A, Muzi M, Specht JM, Doot RK, Link JM, Krohn KA, Kinahan PE, Mankoff DA, Linden HM. F-fluorodeoxyglucose (FDG) PET or F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. Breast Cancer Research : Bcr. 23: 88. PMID 34425871 DOI: 10.1186/s13058-021-01464-1 |
0.421 |
|
| 2021 |
Chitalia R, Viswanath V, Pantel AR, Peterson LM, Gastounioti A, Cohen EA, Muzi M, Karp J, Mankoff DA, Kontos D. Correction to: Functional 4-D clustering for characterizing intratumor heterogeneity in dynamic imaging: evaluation in FDG PET as a prognostic biomarker for breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. PMID 34117509 DOI: 10.1007/s00259-021-05324-0 |
0.389 |
|
| 2021 |
Muzi M, O'Sullivan F, Perk TG, Muzi JP, Mankoff DA, Jeraj R, Duan F, Yu EY. Whole-Body [F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. Tomography (Ann Arbor, Mich.). 7: 139-153. PMID 33923126 DOI: 10.3390/tomography7020013 |
0.353 |
|
| 2021 |
Young AJ, Pantel AR, Viswanath V, Dominguez TL, Makvandi M, Lee H, Li S, Schubert EK, Pryma DA, Farwell MD, Mach RH, Simpkins F, Lin LL, Mankoff DA, Doot RK. Kinetic and static analysis of poly-(adenosine diphosphate-ribose) polymerase-1 (PARP-1) targeted F-FluorThanatrace (F-FTT) PET images of ovarian cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 33863820 DOI: 10.2967/jnumed.121.261894 |
0.377 |
|
| 2021 |
Chitalia R, Viswanath V, Pantel AR, Peterson LM, Gastounioti A, Cohen EA, Muzi M, Karp J, Mankoff DA, Kontos D. Functional 4-D clustering for characterizing intratumor heterogeneity in dynamic imaging: evaluation in FDG PET as a prognostic biomarker for breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. PMID 33677641 DOI: 10.1007/s00259-021-05265-8 |
0.373 |
|
| 2021 |
Mankoff DA, Surti S. PET/MRI for Primary Breast Cancer: A Match Made Better by PET Quantification? Radiology. Imaging Cancer. 3: e200150. PMID 33577625 DOI: 10.1148/rycan.2021200150 |
0.426 |
|
| 2020 |
Meikle SR, Sossi V, Roncali E, Cherry SR, Banati R, Mankoff DA, Jones T, James ML, Sutcliffe J, Ouyang J, Petibon Y, Ma C, El Fakhri G, Surti S, Karp JS, et al. Quantitative PET in the 2020s: A Roadmap. Physics in Medicine and Biology. PMID 33339012 DOI: 10.1088/1361-6560/abd4f7 |
0.358 |
|
| 2020 |
Viswanath V, Zhou R, Lee H, Li S, Cragin A, Doot RK, Mankoff DA, Pantel AR. Kinetic Modeling of F-(2S,4R)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 33277391 DOI: 10.2967/jnumed.120.250977 |
0.372 |
|
| 2020 |
Gillman JA, Pantel AR, Mankoff DA, Edmonds CE. Update on Quantitative Imaging for Predicting and Assessing Response in Oncology. Seminars in Nuclear Medicine. 50: 505-517. PMID 33059820 DOI: 10.1053/J.Semnuclmed.2020.07.002 |
0.503 |
|
| 2020 |
Peterson LM, Kurland BF, Yan F, Novakova-Jiresova A, Gadi VK, Specht JM, Gralow JR, Schubert EK, Link JM, Krohn KA, Eary JF, Mankoff DA, Linden HM. F-Fluoroestradiol (F-FES)-PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32591490 DOI: 10.2967/Jnumed.120.244459 |
0.487 |
|
| 2020 |
Mankoff DA, Pantel A. PET Molecular Imaging as a Tool for Precision Oncology. Radiology. 296: 379-380. PMID 32519934 DOI: 10.1148/Radiol.2020201969 |
0.448 |
|
| 2020 |
McDonald ES, Doot RK, Pantel AR, Farwell MD, Mach RH, Maxwell KN, Mankoff DA. Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial. Jama Oncology. PMID 32297911 DOI: 10.1001/Jamaoncol.2020.0334 |
0.475 |
|
| 2020 |
Muzi M, Wolsztynski E, Fink JR, O'Sullivan JN, O'Sullivan F, Krohn KA, Mankoff DA. Assessment of the Prognostic Value of Radiomic Features in F-FMISO PET Imaging of Hypoxia in Postsurgery Brain Cancer Patients: Secondary Analysis of Imaging Data from a Single-Center Study and the Multicenter ACRIN 6684 Trial. Tomography (Ann Arbor, Mich.). 6: 14-22. PMID 32280746 DOI: 10.18383/j.tom.2019.00023 |
0.35 |
|
| 2020 |
Chitalia R, Viswanath V, Pantel AR, Peterson L, Cohen E, Muzi M, Karp J, Mankoff DA, Kontos D. 4D radiomic biomarker of functional tumor heterogeneity to predict breast cancer recurrence in pretreatment dynamic FDG-PET. Journal of Clinical Oncology. 38: e12573-e12573. DOI: 10.1200/Jco.2020.38.15_Suppl.E12573 |
0.526 |
|
| 2020 |
Manohar P, Peterson L, Wu Q(, Jenkins I, Kurland B, Novakova-Jiresova A, Specht J, Muzi M, Link J, Krohn K, Kinahan P, Mankoff D, Linden H. Abstract P1-01-07: The role of 18F-Fluoroestradiol (FES) and 18F-Fluorodeoxyglucose (FDG) PET imaging in identification of bone metastases in metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-01-07 |
0.464 |
|
| 2019 |
Mankoff DA, Pantel AR, Viswanath V, Karp JS. Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology. Current Pathobiology Reports. 7: 97-108. PMID 37092138 DOI: 10.1007/s40139-019-00202-9 |
0.355 |
|
| 2019 |
McDonald ES, Doot RK, Young AJ, Schubert EK, Pryma DA, Farwell MD, Tchou J, Nayak A, Ziober A, Feldman MD, DeMichele A, Clark AS, Shah PD, Lee H, Carlin SD, ... ... Mankoff DA, et al. Breast Cancer F-ISO-1 Uptake as a Marker of Proliferation Status. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31836680 DOI: 10.2967/Jnumed.119.232363 |
0.529 |
|
| 2019 |
Padakanti PK, Li S, Schmitz A, Mankoff D, Mach RH, Lee HS. Automated synthesis of [C]L-glutamine on Synthra HCN plus synthesis module. Ejnmmi Radiopharmacy and Chemistry. 4: 5. PMID 31659517 DOI: 10.1186/S41181-019-0057-4 |
0.383 |
|
| 2019 |
Pantel AR, Viswanath V, Daube-Witherspoon ME, Dubroff JG, Muehllehner G, Parma MJ, Pryma DA, Schubert EK, Mankoff DA, Karp JS. PennPET Explorer: Human Imaging on a Whole-body Imager. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31562224 DOI: 10.2967/Jnumed.119.231845 |
0.416 |
|
| 2019 |
Mankoff DA, Clark AS. PET oestrogen receptor imaging: ready for the clinic? The Lancet. Oncology. PMID 30846328 DOI: 10.1016/S1470-2045(19)30038-5 |
0.426 |
|
| 2019 |
Lee HS, Pantel AR, Zhou R, Mankoff DA. A PET Glutamate Analogue to Measure Cancer Cell Redox State and Oxidative Stress: Promise and Paradox. Cancer Research. 79: 701-703. PMID 30770365 DOI: 10.1158/0008-5472.Can-18-4034 |
0.359 |
|
| 2019 |
Elmi A, Makvandi M, Weng CC, Hou C, Clark AS, Mach RH, Mankoff DA. Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [F]FLT and [F]ISO-1 PET/CT. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30692100 DOI: 10.1158/1078-0432.Ccr-18-2769 |
0.502 |
|
| 2019 |
Reiss KA, Mick R, O'Hara MH, Teitelbaum UR, Karasic TB, Schneider CJ, O'Dwyer PJ, Karlson D, Cowden S, Fuhrer MJ, Carpenter EL, Pantel AA, Makvandi M, Mankoff DA, Nathanson K, et al. A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy. Journal of Clinical Oncology. 37: TPS4161-TPS4161. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps4161 |
0.343 |
|
| 2019 |
Manohar P, Peterson L, Wu V, Jenkins I, Novakova-Jiresova A, Specht J, Link J, Krohn K, Kinahan P, Mankoff D, Linden H. Abstract PD4-10:18F-fluoroestradiol (FES) and18F-fluorodeoxyglucose (FDG) PET imaging in staging extent of disease in metastatic lobular breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd4-10 |
0.49 |
|
| 2019 |
McDonald E, Carlin S, Maxwell K, Nayak A, Doot R, Pantel A, Farwell, Pryma D, Clark A, Shah P, DeMichele A, Ziober A, Schubert E, Palmer K, Lee H, ... ... Mankoff D, et al. Abstract PD4-07: PET imaging of PARP-1 expression in breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd4-07 |
0.513 |
|
| 2019 |
Binder KAR, Mick R, O'Hara M, Teitelbaum U, Karasic T, Schneider C, O'Dwyer PJ, Carpenter E, Pantel A, Makvandi M, Mankoff D, Nathanson K, Maxwell K, Cowden S, Fuhrer MJ, et al. Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation inBRCA1, BRCA2orPALB2 Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct234 |
0.342 |
|
| 2019 |
Mankoff DA, Pantel AR, Viswanath V, Karp JS. Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology Current Pathobiology Reports. 7: 97-108. DOI: 10.1007/S40139-019-00202-9 |
0.49 |
|
| 2018 |
Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, Gallagher FA, Keshari KR, Kjaer A, Laustsen C, Mankoff DA, Merritt ME, Nelson SJ, Pauly JM, Lee P, et al. Hyperpolarized C MRI: Path to Clinical Translation in Oncology. Neoplasia (New York, N.Y.). 21: 1-16. PMID 30472500 DOI: 10.1016/J.Neo.2018.09.006 |
0.346 |
|
| 2018 |
Kurland BF, Peterson LM, Shields AT, Lee JH, Byrd DW, Novakova-Jiresova A, Muzi M, Specht JM, Mankoff DA, Linden HM, Kinahan PE. Test-retest reproducibility of FDG-PET/CT uptake in cancer patients within a qualified and calibrated local network. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30361381 DOI: 10.2967/Jnumed.118.209544 |
0.462 |
|
| 2018 |
Cochran JM, Busch DR, Leproux A, Zhang Z, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue B, Jiang S, Kaufman PA, Chung SH, ... ... Mankoff D, et al. Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. Journal of Biomedical Optics. 24: 1-11. PMID 30338678 DOI: 10.1117/1.Jbo.24.2.021202 |
0.448 |
|
| 2018 |
Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM. Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 30324461 DOI: 10.1007/S11307-018-1287-7 |
0.441 |
|
| 2018 |
Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, Schuster DM, Siegel BA. The Impact of Positron Emission Tomography with F-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. The Journal of Urology. PMID 30179618 DOI: 10.1016/J.Juro.2018.08.050 |
0.436 |
|
| 2018 |
Elmi A, McDonald ES, Mankoff D. Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging Biomarkers. Pet Clinics. 13: 445-457. PMID 30100082 DOI: 10.1016/J.Cpet.2018.02.007 |
0.505 |
|
| 2018 |
Zhou R, Bagga P, Nath K, Hariharan H, Mankoff D, Reddy R. Glutamate-weighted chemical exchange saturation transfer magnetic resonance imaging (GluCEST MRI) detects glutaminase inhibition in a mouse model of triple-negative breast cancer. Cancer Research. PMID 30072394 DOI: 10.1158/0008-5472.Can-17-3988 |
0.415 |
|
| 2018 |
Pantel AR, Ackerman D, Lee SC, Mankoff DA, Gade TP. Imaging Cancer Metabolism: Underlying Biology and Emerging Strategies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30042161 DOI: 10.2967/Jnumed.117.199869 |
0.418 |
|
| 2018 |
Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, ... ... Mankoff DA, et al. The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. International Journal of Radiation Oncology, Biology, Physics. PMID 29966725 DOI: 10.1016/J.Ijrobp.2018.06.023 |
0.378 |
|
| 2018 |
Mankoff DA, Katz SI. PET imaging for assessing tumor response to therapy. Journal of Surgical Oncology. 118: 362-373. PMID 29938396 DOI: 10.1002/Jso.25114 |
0.523 |
|
| 2018 |
Ratai EM, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Richards T, Kim D, Andronesi OC, Mintz A, Kostakoglu L, Prah M, Ellingson B, Schmainda K, Sorensen G, ... ... Mankoff D, et al. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. Plos One. 13: e0198548. PMID 29902200 DOI: 10.1371/Journal.Pone.0198548 |
0.359 |
|
| 2018 |
Peterson LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, Shields A, Montgomery S, Linden HM, Gralow JR, Gadi VK, Muzi M, Kinahan PE, Mankoff DA, Specht JM. Prospective study of serial F-FDG PET and F-fluoride (F-NaF) PET to predict time to skeletal related events, time-to-progression, and survival in patients with bone-dominant metastatic breast cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29748233 DOI: 10.2967/Jnumed.118.211102 |
0.484 |
|
| 2018 |
Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, et al. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. The Journal of Clinical Investigation. PMID 29509546 DOI: 10.1172/Jci97992 |
0.452 |
|
| 2018 |
Kurland BF, Peterson LM, Linden HM, Mankoff DA. FDG PET and FES PET Predict PFS on Endocrine Therapy-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 249-250. PMID 29298808 DOI: 10.1158/1078-0432.CCR-17-2980 |
0.317 |
|
| 2018 |
Manohar P, Peterson L, Wu V, Jenkins I, Novakova-Jiresova A, Specht JM, Link J, Krohn KA, Kinahan P, Mankoff DA, Linden HM. 18F-Fluoroestradiol (FES) and 18F-Fluorodeoxyglucose (FDG) PET imaging in lobular breast cancer. Journal of Clinical Oncology. 36: 1063-1063. DOI: 10.1200/Jco.2018.36.15_Suppl.1063 |
0.504 |
|
| 2018 |
Linden H, Clark A, Fowler A, Novakova A, Mankoff D, Dehdashti F. Abstract OT1-06-04: [18F] fluoroestradiol (FES) PET as a predictive measure for endocrine therapy in women with newly diagnosed metastatic breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot1-06-04 |
0.513 |
|
| 2018 |
Makvandi M, Pantel A, Schwartz L, Doot R, Simpkins F, Mankoff DA, Mach RH, Lin L. Abstract A054: Real-time imaging of PARP-1 in ovarian cancer Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A054 |
0.506 |
|
| 2017 |
Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, ... ... Mankoff D, et al. Future cancer research priorities in the USA: a Lancet Oncology Commission. The Lancet. Oncology. 18: e653-e706. PMID 29208398 DOI: 10.1016/S1470-2045(17)30698-8 |
0.359 |
|
| 2017 |
Fowler AM, Mankoff DA, Joe BN. Imaging Neoadjuvant Therapy Response in Breast Cancer. Radiology. 285: 358-375. PMID 29045232 DOI: 10.1148/Radiol.2017170180 |
0.484 |
|
| 2017 |
Sellmyer MA, Lee I, Hou C, Weng CC, Li S, Lieberman BP, Zeng C, Mankoff DA, Mach RH. Bacterial infection imaging with [(18)F]fluoropropyl-trimethoprim. Proceedings of the National Academy of Sciences of the United States of America. PMID 28716936 DOI: 10.1073/Pnas.1703109114 |
0.383 |
|
| 2017 |
Kurland BF, Linden HM, Mankoff DA. FDG PET and FES PET Predict PFS on Endocrine Therapy-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 3475. PMID 28674116 DOI: 10.1158/1078-0432.Ccr-17-0479 |
0.393 |
|
| 2017 |
Kung HF, Ploessl K, Mankoff D, Zhu L, Zhou R. Metabolic Imaging of Glutamine in Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28232608 DOI: 10.2967/Jnumed.116.182345 |
0.454 |
|
| 2017 |
Zhou R, Pantel AR, Li S, Lieberman BP, Ploessl K, Choi H, Blankemeyer E, Lee H, Kung H, Mach RH, Mankoff D. [18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple Negative Breast Cancer in Response to Glutaminase Inhibition. Cancer Research. PMID 28202527 DOI: 10.1158/0008-5472.Can-16-1945 |
0.466 |
|
| 2017 |
Wangerin KA, Muzi M, Peterson L, Linden H, Novakova A, Mankoff D, Kinahan P. A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. Physics in Medicine and Biology. PMID 28191877 DOI: 10.1088/1361-6560/Aa6023 |
0.506 |
|
| 2017 |
Sellmyer MA, Lee I, Hou C, Lieberman BP, Zeng C, Mankoff DA, Mach RH. Quantitative PET Reporter Gene Imaging with [(11)C]Trimethoprim. Molecular Therapy : the Journal of the American Society of Gene Therapy. 25: 120-126. PMID 28129108 DOI: 10.1016/J.Ymthe.2016.10.018 |
0.39 |
|
| 2017 |
Chudgar AV, Mankoff DA. Molecular Imaging and Precision Medicine in Breast Cancer. Pet Clinics. 12: 39-51. PMID 27863565 DOI: 10.1016/J.Cpet.2016.08.001 |
0.536 |
|
| 2017 |
Peterson LM, Kurland BF, Novakova A, Lee JH, Specht JM, Muzi M, Romine P, Wu V, Mankoff DA, Kinahan P, Linden HM. The use of 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET in the evaluation of breast cancer heterogeneity. Journal of Clinical Oncology. 35: 11572-11572. DOI: 10.1200/Jco.2017.35.15_Suppl.11572 |
0.535 |
|
| 2017 |
Lin L, Makvandi M, Pantel A, Doot R, Schwartz L, Simpkins F, Mankoff D, Mach R. Abstract AP20: A PILOT STUDY OF A POLY (ADP–RIBOSE) POLYMERASE–1 (PARP) TARGETED NOVEL PET TRACER (18F–FLUOURTHANOTRACE) IN PATIENTS WITH OVARIAN CARCINOMA Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ap20 |
0.496 |
|
| 2017 |
Linden H, Peterson L, Kurland B, Roberts T, Specht J, Shields A, Novakova A, Christopfel R, Byrd D, Muzi M, Mankoff D, Kinahan P. Abstract P4-02-05: Test-retest fidelity of FDG SUVmax in bone and non-boney metastatic breast cancer lesions in local area network PET/CT scanners Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-02-05 |
0.498 |
|
| 2017 |
Mankoff DA. Abstract SY02-03: Imaging cancer metabolism in patients: FDG PET and beyond Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Sy02-03 |
0.499 |
|
| 2017 |
McDonald ES, Pant DK, Pan T, Mankoff DA, Mach RH, Chodosh LA. Abstract 5710:PGRMC1is a biomarker for breast cancer cell proliferation and early relapse Cancer Research. 77: 5710-5710. DOI: 10.1158/1538-7445.Am2017-5710 |
0.388 |
|
| 2017 |
Makvandi M, Pantel A, Schwartz LE, Xu K, Hsieh C, Kim H, Li S, Doot R, Lee S, Simpkins F, Greenberg RA, Mankoff DA, Mach RH, Lin L. Abstract 3716: Exploring the significance of PARP-1 expression for therapy and clinical PET/CT imaging of PARP-1 in ovarian cancer Cancer Research. 77: 3716-3716. DOI: 10.1158/1538-7445.Am2017-3716 |
0.481 |
|
| 2017 |
Pantel AR, Lee H, Li S, Doot RK, Mach RH, Mankoff DA, Zhou R. Abstract 2851: Cellular glutamine pool size change in response to glutaminase inhibition detected by kinetic analysis of [18F](2S,4R)4-fluoroglutamine PET Cancer Research. 77: 2851-2851. DOI: 10.1158/1538-7445.Am2017-2851 |
0.359 |
|
| 2017 |
Chen P, Mankoff DA, Sebro RA. Clinical overview of the current state and future applications of positron emission tomography in bone and soft tissue sarcoma Clinical and Translational Imaging. 5: 343-358. DOI: 10.1007/S40336-017-0236-9 |
0.472 |
|
| 2016 |
Mankoff DA, Farwell MD, Clark AS, Pryma DA. Making Molecular Imaging a Clinical Tool for Precision Oncology: A Review. Jama Oncology. PMID 28033451 DOI: 10.1001/Jamaoncol.2016.5084 |
0.401 |
|
| 2016 |
Huynh PT, Lemeshko SV, Mahoney MC, Newell MS, Bailey L, Barke LD, D'Orsi C, Harvey JA, Hayes MK, Jokich PM, Lee SJ, Lehman CD, Mainiero MB, Mankoff DA, Patel SB, et al. ACR Appropriateness Criteria(®) Stage I Breast Carcinoma. Journal of the American College of Radiology : Jacr. 13: e53-e57. PMID 27814824 DOI: 10.1016/j.jacr.2016.09.024 |
0.314 |
|
| 2016 |
Mainiero MB, Lourenco A, Mahoney MC, Newell MS, Bailey L, Barke LD, D'Orsi C, Harvey JA, Hayes MK, Huynh PT, Jokich PM, Lee SJ, Lehman CD, Mankoff DA, Nepute JA, et al. ACR Appropriateness Criteria Breast Cancer Screening. Journal of the American College of Radiology : Jacr. 13: R45-R49. PMID 27814813 DOI: 10.1016/J.Jacr.2016.09.021 |
0.392 |
|
| 2016 |
Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, et al. Repeatability of 18F-FLT PET in a Multi-Center Study of Patients with High Grade Glioma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27688473 DOI: 10.2967/Jnumed.116.178434 |
0.442 |
|
| 2016 |
Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter P, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman P, Yodh AG, Chung SH, ... ... Mankoff D, et al. Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging (DOSI). Cancer Research. PMID 27527559 DOI: 10.1158/0008-5472.Can-16-0346 |
0.448 |
|
| 2016 |
Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM. Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27342400 DOI: 10.1158/1078-0432.Ccr-16-0362 |
0.541 |
|
| 2016 |
Liao GJ, Clark AS, Schubert EK, Mankoff DA. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27307345 DOI: 10.2967/Jnumed.116.175596 |
0.466 |
|
| 2016 |
Pantel AR, Mankoff DA. Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. Cancer Letters. PMID 27195912 DOI: 10.1016/J.Canlet.2016.05.008 |
0.518 |
|
| 2016 |
Stanton SE, Eary JF, Marzbani EA, Mankoff D, Salazar LG, Higgins D, Childs J, Reichow J, Dang Y, Disis ML. Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo. Journal For Immunotherapy of Cancer. 4: 27. PMID 27190628 DOI: 10.1186/S40425-016-0131-3 |
0.426 |
|
| 2016 |
Gerstner E, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Prah M, Schmainda K, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak D, ... Mankoff DA, et al. ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using 18F-FMISO PET and MRI. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27185374 DOI: 10.1200/Jco.2015.33.15_Suppl.2024 |
0.403 |
|
| 2016 |
Edmonds CE, Makvandi M, Lieberman BP, Xu K, Zeng C, Li S, Hou C, Lee H, Greenberg RA, Mankoff DA, Mach RH. [(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. American Journal of Nuclear Medicine and Molecular Imaging. 6: 94-101. PMID 27069769 |
0.349 |
|
| 2016 |
Currin E, Peterson LM, Schubert EK, Link JM, Krohn KA, Livingston RB, Mankoff DA, Linden HM. Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 144-7. PMID 26850484 DOI: 10.6004/Jnccn.2016.0017 |
0.485 |
|
| 2016 |
McDonald ES, Mankoff DA, Mach RH. Novel Strategies for Breast Cancer Imaging: New Imaging Agents to Guide Treatment. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 57: 69S-74S. PMID 26834105 DOI: 10.2967/Jnumed.115.157925 |
0.427 |
|
| 2016 |
Groheux D, Cochet A, Humbert O, Alberini J, Hindié E, Mankoff D. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer. The Journal of Nuclear Medicine. 57. PMID 26834096 DOI: 10.2967/Jnumed.115.157859 |
0.488 |
|
| 2016 |
Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, et al. Quantitative Imaging in Cancer Clinical Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 284-90. PMID 26773162 DOI: 10.1158/1078-0432.Ccr-14-3336 |
0.419 |
|
| 2016 |
Groheux D, Mankoff D, Espié M, Hindié E. ¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. European Journal of Nuclear Medicine and Molecular Imaging. 43: 983-993. PMID 26758726 DOI: 10.1007/S00259-015-3295-Z |
0.528 |
|
| 2016 |
Makvandi M, Lieberman BP, LeGeyt B, Hou C, Mankoff DA, Mach RH, Pryma DA. The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic. Nuclear Medicine and Biology. 43: 35-41. PMID 26702785 DOI: 10.1016/J.Nucmedbio.2015.10.001 |
0.387 |
|
| 2016 |
Mankoff DA, Edmonds CE, Farwell MD, Pryma DA. Development of Companion Diagnostics. Seminars in Nuclear Medicine. 46: 47-56. PMID 26687857 DOI: 10.1053/J.Semnuclmed.2015.09.002 |
0.424 |
|
| 2016 |
Kurland BF, Muzi M, Peterson LM, Doot RK, Wangerin KA, Mankoff DA, Linden HM, Kinahan PE. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 57: 226-30. PMID 26493206 DOI: 10.2967/Jnumed.115.162289 |
0.477 |
|
| 2016 |
Roberts TK, Peterson L, Kurland B, Novakova A, Shields A, Doot RK, Schubert EK, Gadi VK, Specht JM, Gralow J, Eary JF, Muzi M, Link J, Krohn KA, Mankoff DA, et al. Use of serial 18F-Fluorothymidine (FLT) PET and Ki-67 to predict response to aromatase inhibitors (AI) in women with ER+ breast cancer. Journal of Clinical Oncology. 34: e12039-e12039. DOI: 10.1200/Jco.2016.34.15_Suppl.E12039 |
0.513 |
|
| 2016 |
Specht JM, Peterson L, Novakova A, O'Sullivan JN, O'Sullivan F, Shields A, Montgomery S, Linden HM, Gralow J, Ellis GK, Gadi VK, Barlow WE, Doot RK, Schubert EK, Dunnwald LK, ... ... Mankoff DA, et al. Serial FDG-PET to predict response, time to skeletal related events, and survival in patients with bone-dominant metastatic breast cancer. Journal of Clinical Oncology. 34: 11569-11569. DOI: 10.1200/Jco.2016.34.15_Suppl.11569 |
0.46 |
|
| 2016 |
Lynch M, Mankoff D, Bradbury A, Domchek S, Glick J, Matro J, DeMichele A, Clark A. Abstract P6-01-02: Flourine-18-fluorodeoxyglucose positron emission tomography for the evaluation of response to therapy in bone-dominant metastatic breast cancer: Examination in patients enrolled on UPCC 17113 Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-01-02 |
0.459 |
|
| 2016 |
Edmonds C, Lieberman B, Xu K, Zeng C, Makvandi M, Li S, Hou C, Lee H, Greenberg R, Mankoff D, Mach R. Abstract P5-01-06:18F-radiolabeled PARP-1 inhibitor uptake as a marker of PARP-1 activity in breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P5-01-06 |
0.495 |
|
| 2016 |
Specht J, Partridge S, Chai X, Novakova A, Peterson L, Shields A, Guenthoer J, Linden H, Gralow J, Gadi V, Korde L, Hills D, Hsu L, Hockenbery D, Kinahan P, ... Mankoff D, et al. Abstract P5-01-02: Multimodality molecular imaging with dynamic 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and MRI to evaluate response and resistance to neoadjuvant chemotherapy (NAC) Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P5-01-02 |
0.547 |
|
| 2016 |
Clark AS, DeMichele A, Mankoff D. HER2 imaging in the ZEPHIR study Annals of Oncology. 27: 555-557. DOI: 10.1093/Annonc/Mdw033 |
0.358 |
|
| 2016 |
Groheux D, Mankoff D, Lemarignier C, Cochet A, Humbert O, Champion L, Alberini J-, Hindié E. Impact of molecular and histological subtype of breast cancer on 18FDG-PET/CT imaging: Knowledge gained from recent studies Medecine Nucleaire-Imagerie Fonctionnelle Et Metabolique. 40: 65-71. DOI: 10.1016/J.Mednuc.2015.12.003 |
0.523 |
|
| 2015 |
Wangerin KA, Muzi M, Peterson LM, Linden HM, Novakova A, O'Sullivan F, Kurland BF, Mankoff DA, Kinahan PE. Effect of (18)F-FDG uptake time on lesion detectability in PET imaging of early stage breast cancer. Tomography : a Journal For Imaging Research. 1: 53-60. PMID 26807443 DOI: 10.18383/j.tom.2015.00151 |
0.4 |
|
| 2015 |
Murrey DA, Hall NC, Wright CL, Mankoff DA. Precise Localization of Occult Gastrointestinal Hemorrhage Using Dynamic SPECT/CT. Clinical Nuclear Medicine. PMID 26571449 DOI: 10.1097/Rlu.0000000000001014 |
0.319 |
|
| 2015 |
Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Muzi JP, Pryma DA, Specht JM, Hovanessian-Larsen L, Miliziano J, Mallett S, Shields AF, Mankoff DA, et al. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 1681-9. PMID 26359256 DOI: 10.2967/Jnumed.115.160663 |
0.5 |
|
| 2015 |
Farwell MD, Clark AS, Mankoff DA. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy. Jama Oncology. 1: 421-2. PMID 26181243 DOI: 10.1001/Jamaoncol.2015.0667 |
0.427 |
|
| 2015 |
Muzi M, Peterson LM, O'Sullivan JN, Fink JA, Rajendran JG, McLaughlin LJ, Muzi JP, Mankoff DA, Krohn KA. [F-18]-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients using Image-derived Blood Surrogate Tissue Reference Regions. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26112020 DOI: 10.2967/Jnumed.115.158717 |
0.401 |
|
| 2015 |
Kinahan PE, Mankoff DA, Linden HM. The Value of Establishing the Quantitative Accuracy of PET/CT Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 1133-4. PMID 26089552 DOI: 10.2967/Jnumed.115.159178 |
0.433 |
|
| 2015 |
Mankoff DA, Farwell MD, Clark AS, Pryma DA. How Imaging Can Impact Clinical Trial Design: Molecular Imaging as a Biomarker for Targeted Cancer Therapy. Cancer Journal (Sudbury, Mass.). 21: 218-24. PMID 26049702 DOI: 10.1097/Ppo.0000000000000116 |
0.434 |
|
| 2015 |
Nayate AP, Dubroff JG, Schmitt JE, Nasrallah I, Kishore R, Mankoff D, Pryma DA. Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation. Ajnr. American Journal of Neuroradiology. 36: 1237-44. PMID 25767185 DOI: 10.3174/Ajnr.A4281 |
0.409 |
|
| 2015 |
Eckelman WC, Mankoff DA. Choosing a single target as a biomarker or therapeutic using radioactive probes. Nuclear Medicine and Biology. 42: 421-5. PMID 25684651 DOI: 10.1016/J.Nucmedbio.2015.01.005 |
0.374 |
|
| 2015 |
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin ME, Taub JM, Herman B, Higano CS, Doot RK, Hartfeil D, Febbo PG, Mankoff DA. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 354-60. PMID 25635138 DOI: 10.2967/Jnumed.114.146936 |
0.422 |
|
| 2015 |
Linden HM, Peterson L, Kurland BF, Novakova A, Shields A, Gadi VK, Specht JM, Muzi M, Kinahan P, Mankoff DA. FLT-PET (Fluorothymidine) and Ki-67 to measure effects of a short course of aromatase inhibitor therapy in ER+ breast cancer patients. Journal of Clinical Oncology. 33: e22161-e22161. DOI: 10.1200/Jco.2015.33.15_Suppl.E22161 |
0.492 |
|
| 2015 |
Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter P, Mehta R, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman P, Yodh AG, Chung S, ... ... Mankoff D, et al. Abstract S4-04: Predicting pre-surgical neoadjuvant chemotherapy response in breast cancer using diffuse optical spectroscopic imaging (DOSI): Results from the ACRIN 6691 study Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S4-04 |
0.451 |
|
| 2015 |
Linden HM, Specht J, Peterson L, Kurland B, Shields A, Byrd D, Novakova A, Christofel R, Muzi M, Mankoff D, Paul K. Abstract P5-01-07: Fidelity of FDG-PET in breast cancer: Reproducibility at multiple sites Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-01-07 |
0.523 |
|
| 2015 |
McDonald ES, Zeng C, Mankoff DA, Kossenkov A, Mach RH. Abstract 3791: PGRMC1 expression is significantly up-regulated in triple negative breast cancerin vivowith associated activation of cyclin D1 target genes: Analysis of 1019 invasive breast cancers in the TCGA database Cancer Research. 75: 3791-3791. DOI: 10.1158/1538-7445.Am2015-3791 |
0.421 |
|
| 2015 |
Stanton SE, Eary J, Marzbani E, Mankoff D, Salazar L, Higgins D, Reichow J, Dang Y, Disis ML. Abstract 3135: HER2 specific adoptive T cells shown to localize and infiltrate all sites of disease using combined SPECT and PET imaging Cancer Research. 75: 3135-3135. DOI: 10.1158/1538-7445.Am2015-3135 |
0.423 |
|
| 2015 |
Makvandi M, Lieberman BP, Xu K, Anderson R, Zeng C, Mankoff DA, Pryma DA, Greenberg RA, Mach RH. Abstract C15: Predicting response to PARP inhibitors through quantitative measurements of PARP activity in live BRCA1 mutated cells with a radio-iodinated PARP inhibitor Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C15 |
0.356 |
|
| 2015 |
Mankoff DA. Quantitative imaging as cancer biomarker Proceedings of Spie. 9412: 941217. DOI: 10.1117/12.2085907 |
0.446 |
|
| 2015 |
Holdhoff M, Lodge MA, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Lieberman FS, Leal J, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, et al. NIMG-35RESULTS OF EXPLORATORY 18F-FLT PET IMAGING IN TEN RECURRENT HIGH-GRADE GLIOMA PATIENTS TREATED WITH THE SELECTIVE T-TYPE CALCIUM CHANNEL BLOCKER MIBEFRADIL FOLLOWED BY TEMOZOLOMIDE (ABTC TRIAL 1101) Neuro-Oncology. 17: v161.3-v161. DOI: 10.1093/Neuonc/Nov225.35 |
0.466 |
|
| 2014 |
Moy L, Newell MS, Mahoney MC, Bailey L, Barke LD, Carkaci S, D'Orsi C, Goyal S, Haffty BG, Harvey JA, Hayes MK, Jokich PM, Lee SJ, Mainiero MB, Mankoff DA, et al. ACR Appropriateness Criteria stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. Journal of the American College of Radiology : Jacr. 11: 1160-8. PMID 25444069 DOI: 10.1016/J.Jacr.2014.08.020 |
0.399 |
|
| 2014 |
O'Sullivan F, Muzi M, Mankoff DA, Eary JF, Spence AM, Krohn KA. VOXEL-LEVEL MAPPING OF TRACER KINETICS IN PET STUDIES: A STATISTICAL APPROACH EMPHASIZING TISSUE LIFE TABLES. The Annals of Applied Statistics. 8: 1065-1094. PMID 25392718 DOI: 10.1214/14-Aoas732 |
0.397 |
|
| 2014 |
Doot RK, McDonald ES, Mankoff DA. Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials. Clinical and Translational Imaging. 2: 295-303. PMID 25229053 DOI: 10.1007/S40336-014-0071-1 |
0.501 |
|
| 2014 |
Clark AS, McDonald E, Lynch MC, Mankoff D. Using nuclear medicine imaging in clinical practice: update on PET to guide treatment of patients with metastatic breast cancer. Oncology (Williston Park, N.Y.). 28: 424-30. PMID 25004657 |
0.426 |
|
| 2014 |
Farwell MD, Pryma DA, Mankoff DA. PET/CT imaging in cancer: current applications and future directions. Cancer. 120: 3433-45. PMID 24947987 DOI: 10.1002/Cncr.28860 |
0.517 |
|
| 2014 |
Mountz JM, Yankeelov TE, Rubin DL, Buatti JM, Erikson BJ, Fennessy FM, Gillies RJ, Huang W, Jacobs MA, Kinahan PE, Laymon CM, Linden HM, Mankoff DA, Schwartz LH, Shim H, et al. Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2115-6. PMID 24868025 DOI: 10.1200/Jco.2014.55.8866 |
0.443 |
|
| 2014 |
Harrison RL, Elston BF, Doot RK, Lewellen TK, Mankoff DA, Kinahan PE. A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment. Translational Oncology. 7: 138-46. PMID 24772217 DOI: 10.1593/Tlo.13847 |
0.501 |
|
| 2014 |
Mankoff DA, Pryma DA, Clark AS. Molecular imaging biomarkers for oncology clinical trials. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 525-8. PMID 24614222 DOI: 10.2967/Jnumed.113.126128 |
0.395 |
|
| 2014 |
Loiselle C, Eby PR, Kim JN, Calhoun KE, Allison KH, Gadi VK, Peacock S, Storer BE, Mankoff DA, Partridge SC, Lehman CD. Preoperative MRI improves prediction of extensive occult axillary lymph node metastases in breast cancer patients with a positive sentinel lymph node biopsy. Academic Radiology. 21: 92-8. PMID 24331270 DOI: 10.1016/J.Acra.2013.10.001 |
0.33 |
|
| 2014 |
Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 16: 431-40. PMID 24170452 DOI: 10.1007/S11307-013-0699-7 |
0.448 |
|
| 2014 |
Linden HM, Kurland BF, Link J, Novakova A, Chai X, Specht JM, Gadi VK, Gralow J, Schubert EK, Peterson L, Eary JF, Shields A, Mankoff DA, Krohn KA. A phase II clinical trial of HDACi (vorinostat) and AI therapy in breast cancer with molecular imaging correlates. Journal of Clinical Oncology. 32: 556-556. DOI: 10.1200/Jco.2014.32.15_Suppl.556 |
0.516 |
|
| 2014 |
Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Pryma DA, Specht JM, Hovanessian Larsen L, Miliziano J, Mallett S, Shields AF, Mankoff DA. Phase II study of 3'-deoxy-3'-18F fluorothymidine PET/CT (FLT-PET) in the assessment of early response in locally advanced breast cancer (LABC): Preliminary results of ACRIN 6688. Journal of Clinical Oncology. 32: 526-526. DOI: 10.1200/Jco.2014.32.15_Suppl.526 |
0.499 |
|
| 2013 |
Kurland BF, Doot RK, Linden HM, Mankoff DA, Kinahan PE. Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs. Clinical Trials (London, England). 10: 886-95. PMID 24169628 DOI: 10.1177/1740774513506618 |
0.371 |
|
| 2013 |
Harvey JA, Mahoney MC, Newell MS, Bailey L, Barke LD, D'Orsi C, Hayes MK, Jokich PM, Lee SJ, Lehman CD, Mainiero MB, Mankoff DA, Patel SB, Reynolds HE, Sutherland ML, et al. ACR appropriateness criteria palpable breast masses. Journal of the American College of Radiology : Jacr. 10: 742-9.e1-3. PMID 24091044 DOI: 10.1016/J.Jacr.2013.06.013 |
0.375 |
|
| 2013 |
Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, ... Mankoff DA, et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 753-60; quiz 761. PMID 23847214 DOI: 10.6004/Jnccn.2013.0098 |
0.417 |
|
| 2013 |
Mankoff DA. Radionuclide breast cancer imaging 2013: state of the art. Seminars in Nuclear Medicine. 43: 268-70. PMID 23725988 DOI: 10.1053/J.Semnuclmed.2013.03.002 |
0.429 |
|
| 2013 |
Ke AB, Eyal S, Chung FS, Link JM, Mankoff DA, Muzi M, Unadkat JD. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 437-46. PMID 23359659 DOI: 10.2967/Jnumed.112.111732 |
0.316 |
|
| 2013 |
Mainiero MB, Lourenco A, Mahoney MC, Newell MS, Bailey L, Barke LD, D'Orsi C, Harvey JA, Hayes MK, Huynh PT, Jokich PM, Lee SJ, Lehman CD, Mankoff DA, Nepute JA, et al. ACR Appropriateness Criteria Breast Cancer Screening. Journal of the American College of Radiology : Jacr. 10: 11-4. PMID 23290667 DOI: 10.1016/J.Jacr.2012.09.036 |
0.392 |
|
| 2013 |
Yu EY, Duan F, Muzi M, Gorelick J, Chin B, Alumkal JJ, Taplin M, Herman B, Higano CS, Doot RK, Hartfeil DM, Febbo PG, Mankoff DA. Correlation of 18F-fluoride PET response to dasatinib in castration-resistant prostate cancer bone metastases with progression-free survival: Preliminary results from ACRIN 6687. Journal of Clinical Oncology. 31: 5003-5003. DOI: 10.1200/Jco.2013.31.15_Suppl.5003 |
0.421 |
|
| 2013 |
Linden H, Kurland B, Link J, Novakova A, Chai X, Specht J, Gadi V, Gralow J, Schubert E, Peterson L, Eary J, Shields A, Mankoff D, Krohn K. Abstract P4-01-03: HDACi (vorinostat) in metastatic breast cancer to restore sensitivity to ER-directed (AI) therapy: A phase II clinical trial with FES imaging correlates Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-01-03 |
0.497 |
|
| 2013 |
Linden H, Kurland B, Link J, Novakova A, Chai X, Gadi V, Specht J, Hills D, Gralow J, Schubert E, Korde L, Peterson L, Doot R, Eary J, Shields A, ... ... Mankoff D, et al. Abstract P4-01-02: The role of FLT PET early assessment of response to endocrine therapy for early stage breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-01-02 |
0.496 |
|
| 2013 |
Montgomery S, Barlow W, Linden H, Gralow J, Ellis G, Gadi V, Schubert E, Peterson L, Novakova A, Doot R, Dunnwald L, Mankoff D, Specht J. Abstract P4-01-01: Serial FDG and 18F-fluoride PET predict response to therapy in patients with breast cancer bone metastases Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-01-01 |
0.532 |
|
| 2013 |
Mankoff D. Abstract ES08-2: Predicting tumor response by functional imaging, PET imaging as a functional predictive biomarker Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Es08-2 |
0.489 |
|
| 2012 |
Pryma DA, DeMichele A, Mankoff DA. Evaluating the impact of new imaging tests: promises and pitfalls. Journal of the National Cancer Institute. 104: 1857-8. PMID 23243197 DOI: 10.1093/Jnci/Djs488 |
0.304 |
|
| 2012 |
Muzi M, O'Sullivan F, Mankoff DA, Doot RK, Pierce LA, Kurland BF, Linden HM, Kinahan PE. Quantitative assessment of dynamic PET imaging data in cancer imaging. Magnetic Resonance Imaging. 30: 1203-15. PMID 22819579 DOI: 10.1016/J.Mri.2012.05.008 |
0.464 |
|
| 2012 |
Doot RK, Thompson T, Greer BE, Allberg KC, Linden HM, Mankoff DA, Kinahan PE. Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials. Magnetic Resonance Imaging. 30: 1291-300. PMID 22795929 DOI: 10.1016/J.Mri.2012.06.002 |
0.435 |
|
| 2012 |
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, et al. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : Jnccn. 10: 821-9. PMID 22773798 DOI: 10.6004/Jnccn.2012.0086 |
0.409 |
|
| 2012 |
Huynh PT, Lemeshko SV, Mahoney MC, Newell MS, Bailey L, Barke LD, D'Orsi C, Harvey JA, Hayes MK, Jokich PM, Lee SJ, Lehman CD, Mainiero MB, Mankoff DA, Patel SB, et al. ACR Appropriateness Criteria® stage I breast carcinoma. Journal of the American College of Radiology : Jacr. 9: 463-7. PMID 22748785 DOI: 10.1016/J.Jacr.2012.03.011 |
0.426 |
|
| 2012 |
Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. Ejnmmi Research. 2: 34. PMID 22731662 DOI: 10.1186/2191-219X-2-34 |
0.505 |
|
| 2012 |
Abella M, Alessio AM, Mankoff DA, MacDonald LR, Vaquero JJ, Desco M, Kinahan PE. Accuracy of CT-based attenuation correction in PET/CT bone imaging. Physics in Medicine and Biology. 57: 2477-90. PMID 22481547 DOI: 10.1088/0031-9155/57/9/2477 |
0.403 |
|
| 2012 |
Specht JM, Mankoff DA. Advances in molecular imaging for breast cancer detection and characterization. Breast Cancer Research : Bcr. 14: 206. PMID 22423895 DOI: 10.1186/Bcr3094 |
0.484 |
|
| 2012 |
Mankoff DA, Specht JM, Eubank WB, Kessler L. [¹⁸F]fluorodeoxyglucose positron emission tomography-computed tomography in breast cancer: when... and when not? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1252-4. PMID 22393078 DOI: 10.1200/Jco.2011.40.6975 |
0.534 |
|
| 2012 |
Doot RK, Kurland BF, Kinahan PE, Mankoff DA. Design considerations for using PET as a response measure in single site and multicenter clinical trials. Academic Radiology. 19: 184-90. PMID 22104290 DOI: 10.1016/J.Acra.2011.10.008 |
0.483 |
|
| 2012 |
Linden HM, Kurland BF, Link J, Gadi VK, Specht JM, Gralow J, Schubert EK, Peterson L, Eary JF, Mankoff DA. Vorinostat to restore sensitivity to aromatase inhibitor therapy in metastatic breast cancer: A phase II clinical trial with ER imaging correlates. Journal of Clinical Oncology. 30: TPS3109-TPS3109. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps3109 |
0.491 |
|
| 2012 |
Gerstner ER, Zhang Z, Fink JR, Sorensen GA, L'Heureux D, Heckel ML, Dunning B, Muzi M, Mankoff DA, Barboriak D. ACRIN 6684 assessment of tumor hypoxia in glioblastoma using 18F-fluoromisonidazole with PET and MRI. Journal of Clinical Oncology. 30: TPS10635-TPS10635. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps10635 |
0.428 |
|
| 2012 |
Currin ER, Dunnwald LK, Doot RK, Schubert EK, Kurland BF, Mankoff DA, Specht JM. Quantitative measures of FDG PET after neoadjuvant chemotherapy to predict breast cancer patient survival. Journal of Clinical Oncology. 30: 1088-1088. DOI: 10.1200/Jco.2012.30.15_Suppl.1088 |
0.464 |
|
| 2012 |
Eary JF, Link JM, Mankoff DA, Muzi M, O'Sullivan F, Fink JR, Rockhill JK, Linden HM, Krohn KA. Abstract SY42-02: Novel PET imaging in the clinic: Selecting patient cohorts and measuring early response Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy42-02 |
0.518 |
|
| 2012 |
Mankoff D, Chodosh L. Abstract BS3-2: Molecular Imaging of Breast Cancer: Visualizing In Vivo Breast Cancer Biology Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Bs3-2 |
0.467 |
|
| 2011 |
Mankoff DA, Linden HM, Link J, Kurland BF, Schubert EK, Peterson L, Gadi VK, Specht JM, Shankar L, Eary JF. NCI-sponsored phase II study of [(18)f]fluoroestradiol (FES) as a marker of hormone sensitivity of metastatic breast cancer: Initial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e11104. PMID 28023805 DOI: 10.1200/Jco.2011.29.15_Suppl.E11104 |
0.479 |
|
| 2011 |
Tromberg BJ, Butler JA, Mankoff DA, Isakoff SJ, Hylton NM, Yodh AG, Boas D, Paulsen K, Pogue BW, Kaufman PA, Mehta RS, Carpenter PM, Cerussi A, Zhang Z, Hartfeil DM, et al. ACRIN 6691 monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS249. PMID 28023578 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps249 |
0.443 |
|
| 2011 |
Jolles PR, Kostakoglu L, Bear HD, Idowu MO, Kurdziel KA, Shankar L, Mankoff DA, Duan F, L'Heureux D. ACRIN 6688 phase II study of fluorine-18 3'-deoxy-3' fluorothymidine (FLT) in invasive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS125. PMID 28022932 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps125 |
0.527 |
|
| 2011 |
Linden HM, Kurland BF, Livingston RB, Ellis GK, Gadi VK, Specht JM, Gralow J, Peterson L, Schubert EK, Xiaoyu S, Mankoff DA. Changes in FDG PET SUV and correlation with Ki-67 following 2 weeks of aromatase inhibitor therapy or trastuzumab in a pilot imaging study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e21077. PMID 28022217 DOI: 10.1200/Jco.2011.29.15_Suppl.E21077 |
0.49 |
|
| 2011 |
Currin E, Linden HM, Mankoff DA. Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging. Current Breast Cancer Reports. 3: 205-211. PMID 23105956 DOI: 10.1007/S12609-011-0053-5 |
0.518 |
|
| 2011 |
Peterson LM, Kurland BF, Link JM, Schubert EK, Stekhova S, Linden HM, Mankoff DA. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nuclear Medicine and Biology. 38: 969-78. PMID 21982568 DOI: 10.1016/J.Nucmedbio.2011.03.002 |
0.482 |
|
| 2011 |
Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 1541-9. PMID 21903739 DOI: 10.2967/Jnumed.111.091439 |
0.459 |
|
| 2011 |
Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4799-805. PMID 21750198 DOI: 10.1158/1078-0432.Ccr-10-3321 |
0.463 |
|
| 2011 |
Surti S, Scheuermann J, El Fakhri G, Daube-Witherspoon ME, Lim R, Abi-Hatem N, Moussallem E, Benard F, Mankoff D, Karp JS. Impact of time-of-flight PET on whole-body oncologic studies: a human observer lesion detection and localization study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 712-9. PMID 21498523 DOI: 10.2967/Jnumed.110.086678 |
0.386 |
|
| 2011 |
Eary JF, Link JM, Muzi M, Conrad EU, Mankoff DA, White JK, Krohn KA. Multiagent PET for risk characterization in sarcoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 541-6. PMID 21421714 DOI: 10.2967/Jnumed.110.083717 |
0.463 |
|
| 2011 |
Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, Schubert EK, Muzi M, Mankoff DA. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2400-9. PMID 21364034 DOI: 10.1158/1078-0432.Ccr-10-2649 |
0.471 |
|
| 2011 |
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, ... Mankoff DA, et al. Invasive breast cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 136-222. PMID 21310842 DOI: 10.6004/Jnccn.2011.0016 |
0.388 |
|
| 2011 |
Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, Mankoff DA. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clinical Nuclear Medicine. 36: 192-8. PMID 21285676 DOI: 10.1097/Rlu.0B013E318208F140 |
0.496 |
|
| 2011 |
Eubank WB, Lee JH, Mankoff DA. Positron-emission Tomography Imaging in Breast Cancer Oral History Review. 7: 130. DOI: 10.17925/Ohr.2011.07.2.130 |
0.494 |
|
| 2011 |
Specht J, Kurland B, Dunnwald L, Doot R, Eun J, Schubert E, Partridge S, Ellis G, Gadi V, Gralow J, Linden H, Rodler E, Mankoff D. P2-09-09: Dynamic FDG PET and DCE-MRI To Assess Tumor Metabolism and Blood Flow in Response to Neoadjuvant Sunitinib and Paclitaxel Followed by AC + G-CSF in Patients with Locally-Advanced (LABC) and/or Inflammatory Breast Cancer (IBC). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-09-09 |
0.426 |
|
| 2011 |
Gadi V, Kurland B, Specht J, Rodler E, Korde L, Peterson L, Schubert E, Chai X, Mankoff D, Linden H. P1-06-25: Changes in FDG PET SUV Correlates with Ki-67 Following 2 Weeks of Aromatase Inhibitor Therapy in ER+ Early Stage Breast Cancer, a Pilot Imaging Study. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-06-25 |
0.517 |
|
| 2011 |
Jolles P, Kostakoglu L, Bear H, Idowu M, Kurdziel K, Shankar L, Mankoff D, Duan F, L'Heureux D. OT2-05-03: ACRIN 6688 Phase II Study of Fluorine-18 3′-Deoxy-3′ Fluorothymidine (FLT) in Invasive Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot2-05-03 |
0.537 |
|
| 2011 |
Tromberg B, L'Heureux D, Mankoff D, Zhang Z, Cerussi A, Mehta R, Carpenter P, Butler J, Hylton N, Kaufman P, Pogue B, Paulsen K, Yodh A, Boas D, Isakoff S. OT2-05-02: ACRIN 6691 Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot2-05-02 |
0.465 |
|
| 2010 |
Partridge SC, Vanantwerp RK, Doot RK, Chai X, Kurland BF, Eby PR, Specht JM, Dunnwald LK, Schubert EK, Lehman CD, Mankoff DA. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Magnetic Resonance Imaging : Jmri. 32: 1124-31. PMID 21031518 DOI: 10.1002/Jmri.22362 |
0.504 |
|
| 2010 |
Linden HM, Mankoff DA. Breast cancer and hormonal stimulation: is glycolysis the first sign of response? Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1663-4. PMID 20956476 DOI: 10.2967/Jnumed.110.078329 |
0.382 |
|
| 2010 |
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5260-8. PMID 20847059 DOI: 10.1158/1078-0432.Ccr-10-0994 |
0.45 |
|
| 2010 |
Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison KH, Schubert EK, Mankoff DA. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2803-10. PMID 20460489 DOI: 10.1158/1078-0432.Ccr-10-0026 |
0.453 |
|
| 2010 |
Eyal S, Ke B, Muzi M, Link JM, Mankoff DA, Collier AC, Unadkat JD. Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clinical Pharmacology and Therapeutics. 87: 579-85. PMID 20336065 DOI: 10.1038/Clpt.2010.11 |
0.302 |
|
| 2010 |
Doot RK, Muzi M, Peterson LM, Schubert EK, Gralow JR, Specht JM, Mankoff DA. Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 521-7. PMID 20237040 DOI: 10.2967/Jnumed.109.070052 |
0.403 |
|
| 2010 |
Chung FS, Eyal S, Muzi M, Link JM, Mankoff DA, Kaddoumi A, O'Sullivan F, Hsiao P, Unadkat JD. Positron emission tomography imaging of tissue P-glycoprotein activity during pregnancy in the non-human primate. British Journal of Pharmacology. 159: 394-404. PMID 20002098 DOI: 10.1111/J.1476-5381.2009.00538.X |
0.348 |
|
| 2010 |
O'Sullivan F, Kirrane J, Muzi M, O'Sullivan JN, Spence AM, Mankoff DA, Krohn KA. Kinetic quantitation of cerebral PET-FDG studies without concurrent blood sampling: statistical recovery of the arterial input function. Ieee Transactions On Medical Imaging. 29: 610-24. PMID 19709971 DOI: 10.1109/Tmi.2009.2029096 |
0.367 |
|
| 2010 |
Montgomery SK, Kurland BF, Dunnwald LK, Doot RK, Livingston RB, Allison KH, Schubert EK, Mankoff DA, Specht JM. Use of PET to assess tumor metabolism and blood flow by tumor subtype in locally advanced breast cancer. Journal of Clinical Oncology. 28: 600-600. DOI: 10.1200/Jco.2010.28.15_Suppl.600 |
0.484 |
|
| 2010 |
Mankoff DA. Clinical trials using novel molecular imaging cancer biomarkers: Current status and future directions Clinical Cancer Research. 16. DOI: 10.1158/Diag-10-Ed2B-2 |
0.492 |
|
| 2010 |
Mankoff DA. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer Breast Diseases: a Year Book Quarterly. 21: 236-237. DOI: 10.1016/S1043-321X(10)79569-2 |
0.505 |
|
| 2009 |
Linden HM, Kurland BF, Livingston RB, Ellis GK, Gadi VK, Specht JM, Gralow JR, Mankoff DA, Peterson LM, Schubert EK. Early assessment of response to aromatase inhibitor (AI) therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11075. PMID 27963199 DOI: 10.1200/Jco.2009.27.15_Suppl.11075 |
0.416 |
|
| 2009 |
Carr L, Goulart B, Martins R, Keith E, Kell E, Wallace S, Capell P, Mankoff D. Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6056. PMID 27961933 DOI: 10.1200/Jco.2009.27.15_Suppl.6056 |
0.337 |
|
| 2009 |
Mankoff DA, Lee JH, Eubank WB. Breast Cancer Imaging with Novel PET Tracers. Pet Clinics. 4: 371-80. PMID 27157306 DOI: 10.1016/J.Cpet.2009.10.003 |
0.558 |
|
| 2009 |
Eubank WB, Lee JH, Mankoff DA. Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging. Pet Clinics. 4: 299-312. PMID 20161481 DOI: 10.1016/J.Cpet.2009.09.001 |
0.487 |
|
| 2009 |
Mankoff DA, Dehdashti F. Imaging tumor phenotype: 1 plus 1 is more than 2. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 1567-9. PMID 19759107 DOI: 10.2967/Jnumed.108.061044 |
0.355 |
|
| 2009 |
Mankoff DA, Dunnwald LK, Partridge SC, Specht JM. Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5294-6. PMID 19706819 DOI: 10.1158/1078-0432.Ccr-09-1448 |
0.333 |
|
| 2009 |
Wiseman GA, Pacak K, O'Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, Heiba SI, Serafini AN, Tumeh SS, Khutoryansky N, Jacobson AF. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 1448-54. PMID 19690028 DOI: 10.2967/Jnumed.108.058701 |
0.34 |
|
| 2009 |
Eyal S, Chung FS, Muzi M, Link JM, Mankoff DA, Kaddoumi A, O'Sullivan F, Hebert MF, Unadkat JD. Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 798-806. PMID 19403878 DOI: 10.2967/Jnumed.108.059360 |
0.309 |
|
| 2009 |
Lee JH, Rosen EL, Mankoff DA. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2--response to therapy, other indications, and future directions. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 738-48. PMID 19372493 DOI: 10.2967/Jnumed.108.061416 |
0.472 |
|
| 2009 |
Lee JH, Rosen EL, Mankoff DA. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1--overview, detection, and staging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 569-81. PMID 19289422 DOI: 10.2967/Jnumed.108.053512 |
0.47 |
|
| 2009 |
Specht J, Partridge S, Dunnwald L, Doot R, Schubert E, Kurland B, Gralow J, Linden H, Gadi V, Ellis G, Mankoff D. DCE-MRI and dynamic FDG PET to monitor breast cancer response to neoadjuvant sunitinib in patients with locally-advanced breast cancer. Cancer Research. 69: 6006. DOI: 10.1158/0008-5472.Sabcs-6006 |
0.519 |
|
| 2009 |
Specht J, Kurland B, Dunnwald L, Doot R, Gralow J, Ellis G, Linden H, Livingston R, Schubert E, Mankoff D. Metabolism-perfusion mismatch as assessed by PET varies with breast cancer phenotype and predicts response to neoadjuvant chemotherapy. Cancer Research. 69: 6005. DOI: 10.1158/0008-5472.Sabcs-6005 |
0.5 |
|
| 2009 |
Mankoff DA. Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data Breast Diseases: a Year Book Quarterly. 20: 276-278. DOI: 10.1016/S1043-321X(09)79333-6 |
0.489 |
|
| 2008 |
Mankoff DA. Molecular imaging as a tool for translating breast cancer science. Breast Cancer Research : Bcr. 10: S3. PMID 19091007 DOI: 10.1186/Bcr2126 |
0.455 |
|
| 2008 |
Mankoff DA, Eary JF. Proliferation imaging to measure early cancer response to targeted therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7159-60. PMID 19010830 DOI: 10.1158/1078-0432.Ccr-08-2233 |
0.471 |
|
| 2008 |
Eby PR, Partridge SC, White SW, Doot RK, Dunnwald LK, Schubert EK, Kurland BF, Lehman CD, Mankoff DA. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Academic Radiology. 15: 1246-54. PMID 18790395 DOI: 10.1016/J.Acra.2008.03.019 |
0.486 |
|
| 2008 |
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4449-57. PMID 18626006 DOI: 10.1200/Jco.2007.15.4385 |
0.47 |
|
| 2008 |
Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 149S-63S. PMID 18523071 DOI: 10.2967/Jnumed.107.045963 |
0.359 |
|
| 2008 |
Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, Gown A, Link JM, Tewson T, Krohn KA. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 367-74. PMID 18287268 DOI: 10.2967/Jnumed.107.047506 |
0.422 |
|
| 2008 |
Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J. Research issues affecting preoperative systemic therapy for operable breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 806-13. PMID 18258990 DOI: 10.1200/Jco.2007.15.2983 |
0.389 |
|
| 2008 |
Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 786-90. PMID 18258987 DOI: 10.1200/Jco.2008.15.0243 |
0.422 |
|
| 2008 |
Stelzer KJ, Douglas JG, Mankoff DA, Silbergeld DL, Krohn KA, Laramore GE, Spence AM. Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme. Neuro-Oncology. 10: 88-92. PMID 18055860 DOI: 10.1215/15228517-2007-044 |
0.387 |
|
| 2008 |
Mankoff DA. Impact of PET/CT in Comparison With Same Day Contrast Enhanced CT in Breast Cancer Management Breast Diseases: a Year Book Quarterly. 19: 41-42. DOI: 10.1016/S1043-321X(08)80017-3 |
0.438 |
|
| 2007 |
Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics : a Review Publication of the Radiological Society of North America, Inc. 27: S215-29. PMID 18180228 DOI: 10.1148/Rg.27Si075517 |
0.53 |
|
| 2007 |
Krohn KA, O'Sullivan F, Crowley J, Eary JF, Linden HM, Link JM, Mankoff DA, Muzi M, Rajendran JG, Spence AM, Swanson KR. Challenges in clinical studies with multiple imaging probes. Nuclear Medicine and Biology. 34: 879-85. PMID 17921038 DOI: 10.1016/J.Nucmedbio.2007.07.014 |
0.39 |
|
| 2007 |
Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA. 18F-Fluoroestradiol. Seminars in Nuclear Medicine. 37: 470-6. PMID 17920354 DOI: 10.1053/j.semnuclmed.2007.08.003 |
0.41 |
|
| 2007 |
Yu EY, Mankoff DA. Positron emission tomography imaging as a cancer biomarker. Expert Review of Molecular Diagnostics. 7: 659-72. PMID 17892371 DOI: 10.1586/14737159.7.5.659 |
0.509 |
|
| 2007 |
Parisi MT, Mankoff D. Differentiated Pediatric Thyroid Cancer: Correlates With Adult Disease, Controversies in Treatment Seminars in Nuclear Medicine. 37: 340-356. PMID 17707241 DOI: 10.1053/J.Semnuclmed.2007.05.001 |
0.313 |
|
| 2007 |
Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3460-9. PMID 17575208 DOI: 10.1158/1078-0432.Ccr-07-0074 |
0.555 |
|
| 2007 |
Yao MS, Kurland BF, Smith AH, Schubert EK, Dunnwald LK, Byrd DR, Mankoff DA. Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer. Annals of Surgical Oncology. 14: 2985-93. PMID 17564747 DOI: 10.1245/S10434-007-9473-X |
0.382 |
|
| 2007 |
Rajendran JG, Mankoff DA. Beyond detection: novel applications for PET imaging to guide cancer therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 855-6. PMID 17536105 DOI: 10.2967/Jnumed.107.039768 |
0.489 |
|
| 2007 |
Kanne JP, Mankoff DA, Baird GS, Minoshima S, Livingston RB. Gastric linitis plastica from metastatic breast carcinoma: FDG and FES PET appearances. Ajr. American Journal of Roentgenology. 188: W503-5. PMID 17515338 DOI: 10.2214/Ajr.05.0441 |
0.439 |
|
| 2007 |
Podoloff DA, Advani RH, Allred C, Benson AB, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW, Hillner BE, Hoffman JM, ... ... Mankoff DA, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 5: S1-22; quiz S23-2. PMID 17509259 DOI: 10.6004/Jnccn.2007.2001 |
0.475 |
|
| 2007 |
Doot RK, Dunnwald LK, Schubert EK, Muzi M, Peterson LM, Kinahan PE, Kurland BF, Mankoff DA. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 920-5. PMID 17504870 DOI: 10.2967/Jnumed.106.037382 |
0.478 |
|
| 2007 |
Mankoff DA, O'Sullivan F, Barlow WE, Krohn KA. Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Academic Radiology. 14: 398-405. PMID 17368207 DOI: 10.1016/J.Acra.2007.01.005 |
0.326 |
|
| 2007 |
Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Research and Treatment. 105: 87-94. PMID 17268819 DOI: 10.1007/S10549-006-9435-1 |
0.536 |
|
| 2007 |
Partridge SC, Eby PR, Doot RK, White SW, Kurland BF, Schubert EK, Dunnwald LK, Lehman CD, Mankoff DA. Comparison of vascularity measures from PET and MRI for improved breast tumor characterization and therapeutic response evaluation Journal of Clinical Oncology. 25: 589-589. DOI: 10.1200/Jco.2007.25.18_Suppl.589 |
0.476 |
|
| 2007 |
Mankoff DA, Dunnwald L, Gralow J, Ellis G, Linden H, Specht J, Doot R, Barlow W, Schubert E, Livingston R. Use of changes in blood flow PET measurements to predict post-therapy lymph node status among locally advanced breast cancer patients Journal of Clinical Oncology. 25: 575-575. DOI: 10.1200/Jco.2007.25.18_Suppl.575 |
0.403 |
|
| 2007 |
Dunnwald L, Gralow J, Ellis G, Livingston R, Linden H, Specht J, Doot R, Lawton T, Barlow W, Mankoff D. Tumor metabolism, blood flow changes, and prognosis by positron emission tomography: A prospective cohort of locally advanced breast cancer patients Journal of Clinical Oncology. 25: 506-506. DOI: 10.1200/Jco.2007.25.18_Suppl.506 |
0.496 |
|
| 2007 |
Linden HM, Mankoff DA, Krohn KA, Link JM, Stekhova S, Livingston RB, Gralow JR, Ellis GK, Kurland B, Peterson L, Schubert EK. PET FES measures in vivo pharmacodynamics of endocrine therapy Journal of Clinical Oncology. 25: 14110-14110. DOI: 10.1200/Jco.2007.25.18_Suppl.14110 |
0.445 |
|
| 2006 |
Mankoff DA, Dunnwald LK. Changes in Glucose Metabolism and Blood Flow Following Chemotherapy for Breast Cancer Pet Clinics. 1: 71-81. PMID 27156960 DOI: 10.1016/J.Cpet.2005.09.001 |
0.496 |
|
| 2006 |
Mankoff DA. Radiotracer breast cancer imaging: Beyond FDG and MIBI. Physica Medica : Pm : An International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (Aifb). 21: 12-6. PMID 17645986 DOI: 10.1016/S1120-1797(06)80016-5 |
0.513 |
|
| 2006 |
Mankoff DA, Eubank WB. Current and future use of positron emission tomography (PET) in breast cancer. Journal of Mammary Gland Biology and Neoplasia. 11: 125-36. PMID 17075687 DOI: 10.1007/S10911-006-9019-Z |
0.525 |
|
| 2006 |
Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. European Journal of Nuclear Medicine and Molecular Imaging. 33: 44-53. PMID 16763816 DOI: 10.1007/S00259-006-0135-1 |
0.437 |
|
| 2006 |
Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 1059-66. PMID 16741317 |
0.368 |
|
| 2006 |
Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2793-9. PMID 16682724 DOI: 10.1200/Jco.2005.04.3810 |
0.529 |
|
| 2006 |
Martins RG, Rajendran JG, Capell P, Byrd DR, Mankoff DA. Medullary thyroid cancer: options for systemic therapy of metastatic disease? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1653-5. PMID 16549818 DOI: 10.1200/Jco.2005.05.4106 |
0.306 |
|
| 2006 |
Rostomily RC, Elias M, Deng M, Elias P, Born DE, Muballe D, Silbergeld DL, Futran N, Weymuller EA, Mankoff DA, Eary J. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head & Neck. 28: 305-12. PMID 16470879 DOI: 10.1002/Hed.20356 |
0.386 |
|
| 2006 |
Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE, Krohn KA, Mankoff DA. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Annals of Surgical Oncology. 13: 187-97. PMID 16418883 DOI: 10.1245/Aso.2006.04.022 |
0.496 |
|
| 2006 |
Douglas JG, Stelzer KJ, Mankoff DA, Tralins KS, Krohn KA, Muzi M, Silbergeld DL, Rostomily RC, Scharnhorst J, Spence AM. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. International Journal of Radiation Oncology, Biology, Physics. 64: 886-91. PMID 16242251 DOI: 10.1016/J.Ijrobp.2005.08.013 |
0.425 |
|
| 2006 |
Linden HM, Stekhova S, Link JM, Livingston RB, Gralow JR, Ellis GK, Peterson LM, Schubert EK, Krohn KA, Mankoff DA. Understanding resistance to hormonal therapy in estrogen avid breast cancer Journal of Clinical Oncology. 24: 566-566. DOI: 10.1200/Jco.2006.24.18_Suppl.566 |
0.448 |
|
| 2006 |
Lee JH, Sundararajan L, Eubank WB, Mankoff DA. PET Imaging of Breast Cancer: Beyond Standard FDG Studies Seminars in Breast Disease. 9: 146-154. DOI: 10.1053/J.Sembd.2007.02.007 |
0.558 |
|
| 2005 |
Tam SL, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA. Serial FDG-PET to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 633. PMID 27946081 DOI: 10.1200/Jco.2005.23.16_Suppl.633 |
0.511 |
|
| 2005 |
Mankoff D. Imaging in breast cancer – breast cancer imaging revisited Breast Cancer Research. 7: 276-278. PMID 16457704 DOI: 10.1186/Bcr1359 |
0.534 |
|
| 2005 |
Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, O'Shaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7967-85. PMID 16299226 DOI: 10.1158/1078-0432.Ccr-05-1302 |
0.358 |
|
| 2005 |
Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nuclear Medicine and Biology. 32: 663-71. PMID 16243640 DOI: 10.1016/J.Nucmedbio.2005.04.004 |
0.425 |
|
| 2005 |
Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2785-808. PMID 15837727 DOI: 10.1158/1078-0432.Ccr-04-2626 |
0.536 |
|
| 2005 |
Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging Seminars in Nuclear Medicine. 35: 84-99. PMID 15765372 DOI: 10.1053/J.Semnuclmed.2004.11.001 |
0.547 |
|
| 2005 |
Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, Wells JM, Krohn KA. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 274-82. PMID 15695787 |
0.319 |
|
| 2005 |
Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiologic Clinics of North America. 43: 153-67. PMID 15693654 DOI: 10.1016/J.Rcl.2004.09.005 |
0.526 |
|
| 2005 |
Yao M, Byrd D, Schubert E, Dunnwald L, Anderson B, Moe R, Yeung R, Mann G, Eary J, Mankoff D. Sentinel Node Lymphoscintigraphy and Internal Mammary Nodal Drainage Assessment in Breast Cancer Patients International Journal of Radiation Oncology Biology Physics. 63. DOI: 10.1016/J.Ijrobp.2005.07.398 |
0.377 |
|
| 2004 |
Tseng J, Dunnwald LK, Schubert EK, Link JM, Minoshima S, Muzi M, Mankoff DA. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 45: 1829-37. PMID 15534051 |
0.364 |
|
| 2004 |
Chen X, Moore MO, Lehman CD, Mankoff DA, Lawton TJ, Peacock S, Schubert EK, Livingston RB. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Academic Radiology. 11: 1115-24. PMID 15530804 DOI: 10.1016/J.Acra.2004.07.007 |
0.485 |
|
| 2004 |
Spence AM, Muzi M, Mankoff DA, O'Sullivan SF, Link JM, Lewellen TK, Lewellen B, Pham P, Minoshima S, Swanson K, Krohn KA. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 45: 1653-9. PMID 15471829 |
0.353 |
|
| 2004 |
Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, Mankoff DA. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). American Journal of Clinical Oncology. 27: 407-10. PMID 15289736 DOI: 10.1097/01.Coc.0000128869.19357.9B |
0.524 |
|
| 2004 |
Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seymour M, Livingston R. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer American Journal of Roentgenology. 183: 479-486. PMID 15269044 DOI: 10.2214/Ajr.183.2.1830479 |
0.506 |
|
| 2004 |
Eubank WB, Mankoff DA. Current and future uses of positron emission tomography in breast cancer imaging. Seminars in Nuclear Medicine. 34: 224-240. PMID 15202103 DOI: 10.1053/J.Semnuclmed.2004.03.007 |
0.547 |
|
| 2004 |
Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2245-52. PMID 15073099 DOI: 10.1158/1078-0432.Ccr-0688-3 |
0.427 |
|
| 2003 |
Spence AM, Mankoff DA, Muzi M. Positron emission tomography imaging of brain tumors. Neuroimaging Clinics of North America. 13: 717-39. PMID 15024957 DOI: 10.1016/S1052-5149(03)00097-2 |
0.473 |
|
| 2003 |
Mankoff DA, Muzi M, Krohn KA. Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method? Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 5: 281-5. PMID 14630508 DOI: 10.1016/J.Mibio.2003.09.002 |
0.433 |
|
| 2003 |
Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 44: 1482-8. PMID 12960196 |
0.317 |
|
| 2003 |
Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P, Lewellen B, Mankoff DA. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 44: 1044-50. PMID 12843218 |
0.384 |
|
| 2002 |
Wells JM, Mankoff DA, Muzi M, O'Sullivan F, Eary JF, Spence AM, Krohn KA. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis. Molecular Imaging. 1: 151-9. PMID 12920853 DOI: 10.1162/153535002760235454 |
0.371 |
|
| 2002 |
Wells JM, Mankoff DA, Eary JF, Spence AM, Muzi M, O'Sullivan F, Vernon CB, Link JM, Krohn KA. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Molecular Imaging. 1: 145-50. PMID 12920852 DOI: 10.1162/153535002760235445 |
0.398 |
|
| 2002 |
Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Charlop AW, Tseng J, Rinn KJ, Livingston RB. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nuclear Medicine and Biology. 29: 719-27. PMID 12381452 DOI: 10.1016/S0969-8051(02)00333-5 |
0.418 |
|
| 2002 |
Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB, Mankoff DA. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Academic Radiology. 9: 913-21. PMID 12186440 DOI: 10.1016/S1076-6332(03)80461-0 |
0.502 |
|
| 2002 |
Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Schubert EK, Dunnwald LK, Lindsley SK, Gralow JR, Austin-Seymour MM, Ellis GK, Livingston RB. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics : a Review Publication of the Radiological Society of North America, Inc. 22: 5-17. PMID 11796893 DOI: 10.1148/Radiographics.22.1.G02Ja055 |
0.521 |
|
| 2001 |
Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, Gralow JR, Charlop A, Ellis GK, Lindsley KL, Austin-Seymour MM, Funkhouser CP, Livingston RB. 18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer Journal of Clinical Oncology. 19: 3516-3523. PMID 11481358 DOI: 10.1200/Jco.2001.19.15.3516 |
0.474 |
|
| 2001 |
Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy Journal of Clinical Pharmacology. 41. PMID 11452736 DOI: 10.1177/0091270001417014 |
0.432 |
|
| 2001 |
Byrd DR, Dunnwald LK, Mankoff DA, Anderson BO, Moe RE, Yeung RS, Schubert EK, Eary JF. Internal mammary lymph node drainage patterns in patients with breast cancer documented by breast lymphoscintigraphy Annals of Surgical Oncology. 8: 234-240. PMID 11314940 DOI: 10.1007/S10434-001-0234-Y |
0.36 |
|
| 2001 |
Mankoff DA, Bellon JR. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Seminars in Radiation Oncology. 11: 16-27. PMID 11146039 DOI: 10.1053/Srao.2001.18100 |
0.494 |
|
| 2000 |
Welcsh PL, Mankoff DA. Cancer: Taking up iodide in breast tissue Nature. 406: 688. PMID 10963582 DOI: 10.1038/35021173 |
0.38 |
|
| 2000 |
Mankoff DA, Dehdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia (New York, N.Y.). 2: 71-88. PMID 10933070 DOI: 10.1038/Sj.Neo.7900075 |
0.49 |
|
| 1999 |
Jones A, Bernstein V, Davis N, Bryce C, Wilson D, Mankoff D. Pilot Feasibility Study to Assess the Utility of PET Scanning in the Pre-Operative Evaluation of Internal Mammary Nodes in Breast Cancer Patients Presenting with Medial Hemisphere Tumors. Clinical Positron Imaging : Official Journal of the Institute For Clinical P.E.T. 2: 331. PMID 14516628 DOI: 10.1016/S1095-0397(99)00091-6 |
0.47 |
|
| 1999 |
Tewson TJ, Mankoff DA, Peterson LM, Woo I, Petra P. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nuclear Medicine and Biology. 26: 905-13. PMID 10708304 DOI: 10.1016/S0969-8051(99)00072-4 |
0.357 |
|
| 1999 |
Eary JF, Mankoff DA, Dunnwald LK, Byrd DR, Anderson BO, Yeung RS, Moe RE. Sentinel lymph node mapping for breast cancer: Analysis in a diverse patient group Radiology. 213: 526-529. PMID 10551236 DOI: 10.1148/Radiology.213.2.R99Oc27526 |
0.308 |
|
| 1999 |
Hathaway PB, Mankoff DA, Maravilla KR, Austin-Seymour MM, Ellis GK, Gralow JR, Cortese AA, Hayes CE, Moe RE. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience Radiology. 210: 807-814. PMID 10207485 DOI: 10.1148/Radiology.210.3.R99Mr43807 |
0.562 |
|
| 1998 |
Eubank WB, Mankoff DA, Schmiedl UP, Winter TC, Fisher ER, Olshen AB, Graham MM, Eary JF. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. American Journal of Roentgenology. 171: 1103-1110. PMID 9763005 DOI: 10.2214/Ajr.171.4.9763005 |
0.437 |
|
| 1997 |
Lehr H, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer Journal of Histochemistry and Cytochemistry. 45: 1559-1565. PMID 9358857 DOI: 10.1177/002215549704501112 |
0.425 |
|
| 1997 |
Mankoff DA, Thompson JA, Gold P, Eary JF, Guinee DG, Samlowski WE. Identification of interleukin-2-induced complete response in metastatic renal cell carcinoma by FDG PET despite radiographic evidence suggesting persistent tumor American Journal of Roentgenology. 169: 1049-1050. PMID 9308463 DOI: 10.2214/Ajr.169.4.9308463 |
0.388 |
|
| 1997 |
Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16α-Fluorestradiol (FES) Nuclear Medicine and Biology. 24: 341-348. PMID 9257333 DOI: 10.1016/S0969-8051(97)00002-4 |
0.352 |
|
| 1995 |
Dunnwald LK, Mankoff DA, Hartnett SD. Semi-Quantitative Analysis In Sestamibi Breast Imaging Clinical Nuclear Medicine. 20: 859. DOI: 10.1097/00003072-199509000-00052 |
0.406 |
|
| 1995 |
Mankoff DA, Dunnwald LK, Drucker M. Breast Cancer Imaging With Tc-99M Sestamibi: Correlation Of Semi-Quantitative Indices Of Uptake With Pathology Clinical Nuclear Medicine. 20: 857. DOI: 10.1097/00003072-199509000-00044 |
0.442 |
|
| 1994 |
Mankoff DA, Graham MM. Cost Effectiveness Considerations in Nuclear Medicine BREAST CANCER IMAGING Clinical Nuclear Medicine. 19: 841. DOI: 10.1097/00003072-199409000-00038 |
0.413 |
|
| 1991 |
Karp JS, Kinahan PE, Mankoff DA. Positron Emission Tomography with a Large Axial Acceptance Angle: Signal-To-Noise Considerations Ieee Transactions On Medical Imaging. 10: 249-255. DOI: 10.1109/42.97572 |
0.342 |
|
| 1988 |
Muehllehner G, Karp JS, Mankoff DA, Beerbohm D, Ordonez CE. Design and performance of a new positron tomograph Ieee Transactions On Nuclear Science. 35: 670-674. DOI: 10.1109/23.12809 |
0.342 |
|
| 1988 |
Mankoff DA, Muehllehner G, Karp JS. The effect of detector performance on high count rate PET imaging with a tomograph based on position-sensitive detectors Ieee Transactions On Nuclear Science. 35: 592-597. DOI: 10.1109/23.12793 |
0.352 |
|
| 1986 |
Mankoff D, Muehllehner G. Multi-Frame Data Acquisition for PET Camera Using an On-Line Microprocessor-Based System Ieee Transactions On Nuclear Science. 33: 443-445. DOI: 10.1109/Tns.1986.4337139 |
0.319 |
|
| Show low-probability matches. |